Viking Therapeutics price target lowered to $95 from $120 at Truist

Truist lowered the firm’s price target on Viking Therapeutics (VKTX) to $95 from $120 and keeps a Buy rating on the shares. The company’s Q4 update narrowed the timeline for the start of two Phase 3 studies of SQVK2735 in obesity, and while the toplines from Phase 3 won’t come until late 2026/2027, the Phase 2 Oral VK2735 topline in the second half of this year and IND of amylin are key near-term catalysts, the analyst tells investors in a research note. Truist adds however that it is removing VK2809 from its sum of parts valuation model on reduced visibility on path forward.